IDYA
Price
$35.68
Change
+$0.27 (+0.76%)
Updated
Dec 24 closing price
Capitalization
3.13B
95 days until earnings call
Intraday BUY SELL Signals
OCUL
Price
$12.71
Change
-$0.03 (-0.24%)
Updated
Dec 24 closing price
Capitalization
2.71B
73 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs OCUL

Header iconIDYA vs OCUL Comparison
Open Charts IDYA vs OCULBanner chart's image
IDEAYA Biosciences
Price$35.68
Change+$0.27 (+0.76%)
Volume$355.13K
Capitalization3.13B
Ocular Therapeutix
Price$12.71
Change-$0.03 (-0.24%)
Volume$922.36K
Capitalization2.71B
IDYA vs OCUL Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. OCUL commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and OCUL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (IDYA: $35.68 vs. OCUL: $12.71)
Brand notoriety: IDYA and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 35% vs. OCUL: 31%
Market capitalization -- IDYA: $3.13B vs. OCUL: $2.71B
IDYA [@Biotechnology] is valued at $3.13B. OCUL’s [@Biotechnology] market capitalization is $2.71B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 4 bearish.
  • OCUL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, OCUL is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +5.78% price change this week, while OCUL (@Biotechnology) price change was -7.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

OCUL is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($3.13B) has a higher market cap than OCUL($2.71B). OCUL YTD gains are higher at: 48.829 vs. IDYA (38.833). IDYA has higher annual earnings (EBITDA): -204.84M vs. OCUL (-233.54M). IDYA has more cash in the bank: 787M vs. OCUL (345M). IDYA has less debt than OCUL: IDYA (27.2M) vs OCUL (77M). IDYA has higher revenues than OCUL: IDYA (215M) vs OCUL (55.8M).
IDYAOCULIDYA / OCUL
Capitalization3.13B2.71B116%
EBITDA-204.84M-233.54M88%
Gain YTD38.83348.82980%
P/E RatioN/AN/A-
Revenue215M55.8M385%
Total Cash787M345M228%
Total Debt27.2M77M35%
FUNDAMENTALS RATINGS
IDYA vs OCUL: Fundamental Ratings
IDYA
OCUL
OUTLOOK RATING
1..100
6666
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
53
Fair valued
PROFIT vs RISK RATING
1..100
57100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
3944
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (27) in the null industry is in the same range as OCUL (53) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's Profit vs Risk Rating (57) in the null industry is somewhat better than the same rating for OCUL (100) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew somewhat faster than OCUL’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as OCUL (98) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's Price Growth Rating (39) in the null industry is in the same range as OCUL (44) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

IDYA's P/E Growth Rating (100) in the null industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that IDYA’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAOCUL
RSI
ODDS (%)
Bearish Trend 3 days ago
68%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 19 days ago
78%
Declines
ODDS (%)
Bearish Trend 9 days ago
75%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
OCUL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BEMRX12.280.03
+0.24%
Brandes Emerging Markets Value R6
FIMPX38.730.06
+0.16%
Nuveen Small Cap Growth Opp I
FTWRX17.880.02
+0.11%
Templeton World R6
VALAX29.51N/A
N/A
Al Frank Adv
TRZLX43.17N/A
N/A
T. Rowe Price US Large-Cap Core Z

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.76%
NUVL - IDYA
59%
Loosely correlated
+0.89%
XENE - IDYA
58%
Loosely correlated
+1.06%
XNCR - IDYA
57%
Loosely correlated
-0.13%
CGON - IDYA
55%
Loosely correlated
+0.22%
IMTX - IDYA
54%
Loosely correlated
+1.47%
More

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with WVE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then WVE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-0.24%
WVE - OCUL
56%
Loosely correlated
+4.41%
NRIX - OCUL
54%
Loosely correlated
+0.36%
KYMR - OCUL
52%
Loosely correlated
-0.48%
IDYA - OCUL
51%
Loosely correlated
+0.76%
EYPT - OCUL
51%
Loosely correlated
-0.65%
More